Effect of PPAR-α and -γ agonist on the expression of visfatin, adiponectin, and TNF-α in visceral fat of OLETF rats

K. C. Choi, O. H. Ryu, K. W. Lee, H. Y. Kim, Ji A Seo, Sin Gon Kim, Nan Hee Kim, D. S. Choi, Sei-Hyun Baik, Kyung Mook Choi

Research output: Contribution to journalArticle

129 Citations (Scopus)

Abstract

A variety of adipocytokines and peptides secreted from adipocytes have been considered to play a crucial role in obesity, insulin resistance, and type 2 diabetes. Recently, visfatin, a new adipocytokine, known as a pre-B cell colony-enhancing factor, has been isolated from visceral fat deposits. It has been shown to activate insulin receptors in a manner different from insulin. To understand the role of adipocytokines in improving insulin sensitivity via activation of the nuclear receptor peroxisome proliferator-activated receptor-α (PPAR-α) and -γ (PPAR-γ), we examined the expression of visfatin, adiponectin, and TNF-α in visceral fat depots of Otsuka Long-Evans Tokushima fatty (OLETF) rats from early to advanced diabetic stage (from 28 to 40 weeks of age). Serum glucose and insulin concentrations significantly (P < 0.05) decreased in rosiglitazone or fenofibrate-treated OLETF rats compared to untreated OLETF rats. Rosiglitazone significantly increased serum adiponectin concentration from 20 to 40 weeks of age (P < 0.05), whereas fenofibrate reduced TNF-α concentration. The expression of visfatin and adiponectin mRNA in visceral fat deposits was elevated by rosiglitazone or fenofibrate treatments when compared to untreated OLETF rats (P < 0.05), whereas, TNF-α mRNA was down-regulated by these drugs (P < 0.05). These results suggest that rosiglitazone and fenofibrate may prevent type 2 diabetes by regulating adipocytokines including visfatin, adiponectin, and TNF-α.

Original languageEnglish
Pages (from-to)747-753
Number of pages7
JournalBiochemical and Biophysical Research Communications
Volume336
Issue number3
DOIs
Publication statusPublished - 2005 Oct 28

Fingerprint

rosiglitazone
Inbred OLETF Rats
Nicotinamide Phosphoribosyltransferase
Peroxisome Proliferator-Activated Receptors
Intra-Abdominal Fat
Adiponectin
Fenofibrate
Adipokines
Rats
Fats
Insulin
Medical problems
Type 2 Diabetes Mellitus
Insulin Resistance
Deposits
Messenger RNA
Insulin Receptor
Cytoplasmic and Nuclear Receptors
Serum
Adipocytes

Keywords

  • Adipocytokines
  • Fenofibrate
  • Insulin resistance
  • Rosiglitazone
  • TNF-α
  • Type 2 diabetes
  • Visfatin

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Effect of PPAR-α and -γ agonist on the expression of visfatin, adiponectin, and TNF-α in visceral fat of OLETF rats. / Choi, K. C.; Ryu, O. H.; Lee, K. W.; Kim, H. Y.; Seo, Ji A; Kim, Sin Gon; Kim, Nan Hee; Choi, D. S.; Baik, Sei-Hyun; Choi, Kyung Mook.

In: Biochemical and Biophysical Research Communications, Vol. 336, No. 3, 28.10.2005, p. 747-753.

Research output: Contribution to journalArticle

@article{f4b8847c766142f5b018eec64c8f969a,
title = "Effect of PPAR-α and -γ agonist on the expression of visfatin, adiponectin, and TNF-α in visceral fat of OLETF rats",
abstract = "A variety of adipocytokines and peptides secreted from adipocytes have been considered to play a crucial role in obesity, insulin resistance, and type 2 diabetes. Recently, visfatin, a new adipocytokine, known as a pre-B cell colony-enhancing factor, has been isolated from visceral fat deposits. It has been shown to activate insulin receptors in a manner different from insulin. To understand the role of adipocytokines in improving insulin sensitivity via activation of the nuclear receptor peroxisome proliferator-activated receptor-α (PPAR-α) and -γ (PPAR-γ), we examined the expression of visfatin, adiponectin, and TNF-α in visceral fat depots of Otsuka Long-Evans Tokushima fatty (OLETF) rats from early to advanced diabetic stage (from 28 to 40 weeks of age). Serum glucose and insulin concentrations significantly (P < 0.05) decreased in rosiglitazone or fenofibrate-treated OLETF rats compared to untreated OLETF rats. Rosiglitazone significantly increased serum adiponectin concentration from 20 to 40 weeks of age (P < 0.05), whereas fenofibrate reduced TNF-α concentration. The expression of visfatin and adiponectin mRNA in visceral fat deposits was elevated by rosiglitazone or fenofibrate treatments when compared to untreated OLETF rats (P < 0.05), whereas, TNF-α mRNA was down-regulated by these drugs (P < 0.05). These results suggest that rosiglitazone and fenofibrate may prevent type 2 diabetes by regulating adipocytokines including visfatin, adiponectin, and TNF-α.",
keywords = "Adipocytokines, Fenofibrate, Insulin resistance, Rosiglitazone, TNF-α, Type 2 diabetes, Visfatin",
author = "Choi, {K. C.} and Ryu, {O. H.} and Lee, {K. W.} and Kim, {H. Y.} and Seo, {Ji A} and Kim, {Sin Gon} and Kim, {Nan Hee} and Choi, {D. S.} and Sei-Hyun Baik and Choi, {Kyung Mook}",
year = "2005",
month = "10",
day = "28",
doi = "10.1016/j.bbrc.2005.08.203",
language = "English",
volume = "336",
pages = "747--753",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Effect of PPAR-α and -γ agonist on the expression of visfatin, adiponectin, and TNF-α in visceral fat of OLETF rats

AU - Choi, K. C.

AU - Ryu, O. H.

AU - Lee, K. W.

AU - Kim, H. Y.

AU - Seo, Ji A

AU - Kim, Sin Gon

AU - Kim, Nan Hee

AU - Choi, D. S.

AU - Baik, Sei-Hyun

AU - Choi, Kyung Mook

PY - 2005/10/28

Y1 - 2005/10/28

N2 - A variety of adipocytokines and peptides secreted from adipocytes have been considered to play a crucial role in obesity, insulin resistance, and type 2 diabetes. Recently, visfatin, a new adipocytokine, known as a pre-B cell colony-enhancing factor, has been isolated from visceral fat deposits. It has been shown to activate insulin receptors in a manner different from insulin. To understand the role of adipocytokines in improving insulin sensitivity via activation of the nuclear receptor peroxisome proliferator-activated receptor-α (PPAR-α) and -γ (PPAR-γ), we examined the expression of visfatin, adiponectin, and TNF-α in visceral fat depots of Otsuka Long-Evans Tokushima fatty (OLETF) rats from early to advanced diabetic stage (from 28 to 40 weeks of age). Serum glucose and insulin concentrations significantly (P < 0.05) decreased in rosiglitazone or fenofibrate-treated OLETF rats compared to untreated OLETF rats. Rosiglitazone significantly increased serum adiponectin concentration from 20 to 40 weeks of age (P < 0.05), whereas fenofibrate reduced TNF-α concentration. The expression of visfatin and adiponectin mRNA in visceral fat deposits was elevated by rosiglitazone or fenofibrate treatments when compared to untreated OLETF rats (P < 0.05), whereas, TNF-α mRNA was down-regulated by these drugs (P < 0.05). These results suggest that rosiglitazone and fenofibrate may prevent type 2 diabetes by regulating adipocytokines including visfatin, adiponectin, and TNF-α.

AB - A variety of adipocytokines and peptides secreted from adipocytes have been considered to play a crucial role in obesity, insulin resistance, and type 2 diabetes. Recently, visfatin, a new adipocytokine, known as a pre-B cell colony-enhancing factor, has been isolated from visceral fat deposits. It has been shown to activate insulin receptors in a manner different from insulin. To understand the role of adipocytokines in improving insulin sensitivity via activation of the nuclear receptor peroxisome proliferator-activated receptor-α (PPAR-α) and -γ (PPAR-γ), we examined the expression of visfatin, adiponectin, and TNF-α in visceral fat depots of Otsuka Long-Evans Tokushima fatty (OLETF) rats from early to advanced diabetic stage (from 28 to 40 weeks of age). Serum glucose and insulin concentrations significantly (P < 0.05) decreased in rosiglitazone or fenofibrate-treated OLETF rats compared to untreated OLETF rats. Rosiglitazone significantly increased serum adiponectin concentration from 20 to 40 weeks of age (P < 0.05), whereas fenofibrate reduced TNF-α concentration. The expression of visfatin and adiponectin mRNA in visceral fat deposits was elevated by rosiglitazone or fenofibrate treatments when compared to untreated OLETF rats (P < 0.05), whereas, TNF-α mRNA was down-regulated by these drugs (P < 0.05). These results suggest that rosiglitazone and fenofibrate may prevent type 2 diabetes by regulating adipocytokines including visfatin, adiponectin, and TNF-α.

KW - Adipocytokines

KW - Fenofibrate

KW - Insulin resistance

KW - Rosiglitazone

KW - TNF-α

KW - Type 2 diabetes

KW - Visfatin

UR - http://www.scopus.com/inward/record.url?scp=25144517287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25144517287&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2005.08.203

DO - 10.1016/j.bbrc.2005.08.203

M3 - Article

VL - 336

SP - 747

EP - 753

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 3

ER -